Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
Completed
Japan Cardiovascular Research Foundation
Phase 4
2004-08-01
Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a
selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and
have frequently been used for the treatment of acute brain infarction in Japan. The effect of
combination therapy of these drugs, however, has not yet been elucidated. This study will
test the safety and efficacy of the combination therapy with these agents in patients with
acute non-cardioembolic and non-lacunar ischemic stroke.
Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
Completed
Combination Therapy for Acute Ischemic Stroke Study Group
Phase 4
2004-08-01
Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a
selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and
have frequently been used for the treatment of acute brain infarction in Japan. The effect of
combination therapy of these drugs, however, has not yet been elucidated. This study will
test the safety and efficacy of the combination therapy with these agents in patients with
acute non-cardioembolic and non-lacunar ischemic stroke.
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Completed
Mitsubishi Tanabe Pharma Corporation
Phase 4
2004-08-01
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study
on acute ischemic stroke. The primary endpoints were the rate of patients with modified
Rankin Scale score of 0-1 at 3 months.
Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Completed
Japan Heart Foundation
Phase 4
2001-04-01
Early reperfusion therapy has improved the clinical outcomes of patients with acute
myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion
injuries. There is now increasing evidence that reactive oxygen species cause reperfusion
injury. This study was designed to examine the effects of edaravone, a novel free radical
scavenger, in patients with AMI.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
